Evidence map›Paper›PMID 39068447›Full record

SynthesisEuropean journal of medical research2024

Comparative effectiveness of ultrathin vs. standard strut drug-eluting stents: insights from a large-scale meta-analysis with extended follow-up.

Ahmed Hassan, Ahmed Mazen Amin, Ahmed Farid Gadelmawla, Ahmed Mansour, Hamed Abdelma'aboud Mostafa, Mariam Tarek Desouki, Mostafa Mahmoud Naguib, Bilal Ali, Aisha Siraj, Mustafa Suppah and 1 more

Abstract readMeta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ahmed HassanFaculty of Medicine, October 6 University, Giza, Egypt. 20161300@o6u.edu.eg.
Ahmed Mazen AminFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Ahmed Farid GadelmawlaFaculty of Medicine, Menoufia University, Menoufia, Egypt.
Ahmed MansourFaculty of Medicine, Al-Azhar University, Cairo, Egypt.
Hamed Abdelma'aboud MostafaFaculty of Medicine, Al-Azhar University, Damietta, Egypt.
Mariam Tarek DesoukiFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Mostafa Mahmoud NaguibFaculty of Medicine, Al-Azhar University, Damietta, Egypt.
Bilal AliUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Aisha SirajMetroHealth Medical Center, Case Western Reserve University, Cleveland Heights, OH, USA.
Mustafa SuppahDepartment of Cardiovascular Medicine, Mayo Clinic, Arizona, USA.
Diaa HakimDepartment of Cardiology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNewer generation ultrathin strut stents are associated with less incidence of target lesion failure (TLF) in patients undergoing percutaneous coronary intervention (PCI) in the short term. However, its long-term effect on different cardiovascular outcomes remains unknown.

objectivesWe aim to identify the effects of newer-generation ultrathin-strut stents vs. standard thickness second-generation drug-eluting stents (DES) on long-term outcomes of revascularization in coronary artery disease.

methodsWe searched PubMed, Web of Science, Cochrane Library databases, and Scopus for randomized controlled trials (RCTs) and registries that compare newer-generation ultrathin-strut (< 70 mm) with thicker strut (> 70 mm) DES to evaluate cardioprotective effects over a period of up to 5 years. Primary outcome was TLF, a composite of cardiac death, target vessel myocardial infarction (TVMI) or target lesion revascularization (TLR). Secondary outcomes included the components of TLF, stent thrombosis (ST), and all-cause death were pooled as the standardized mean difference between the two groups from baseline to endpoint.

resultsWe included 19 RCTs and two prospective registries (103,101 patients) in this analysis. The overall effect on the primary outcome was in favor of second-generation ultrathin struts stents in terms of TLF at ≥ 1 year, ≥ 2 years, and ≥ 3 years (P value = 0.01, 95% CI [0.75, 0.96]), P value = 0.003, 95% CI [0.77, 0.95]), P value = 0.007, 95% CI [0.76, 0.96]), respectively. However, there was no reported benefit in terms of TLF when we compared the two groups at ≥ 5 years (P value = 0.21), 95% CI [0.85, 1.04]). Some of the reported components of the primary and secondary outcomes, such as TLR, target vessel revascularization (TVR), and TVMI, showed the same pattern as the TLF outcome.

conclusionUltrathin-strut DES showed a beneficial effect over thicker strut stents for up to 3 years. However, at the 5-year follow-up, the ultrathin strut did not differ in terms of TLF, TLR, TVR, and TVMI compared with standard-thickness DES, with similar risks of patient-oriented composite endpoint (POCE), MI, ST, cardiac death, and all-cause mortality.

Indexed as

Coronary Artery DiseaseDrug-Eluting StentsPercutaneous Coronary InterventionFollow-Up StudiesHumansRandomized Controlled Trials as TopicTreatment OutcomeDESMeta-analysisPercutaneous coronary interventionUltrathin-strut drug-eluting stent

Identifiers

PMID39068447
PMCPMC11282633

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.